Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
“Can CAR T-cells cure autoimmune disease?”

Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France
“Resetting the System – Autologous Stem Cell Transplantation Revisited”

Tobias Alexander, Charité-Universitätsmedizin Berlin, Berlin, Germany
“Bispecific T Cell Engagers – Bridging Specificity and Safety”

Huji Xu, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
“Allo in One: Allogeneic CAR T and NK Cells for Treatment-Refractory Autoimmunity”

Harald Prüß, Charité – Universitätsmedizin Berlin, Berlin, Germany
“From Blunt Force to Precision: CAAR T Cells in Autoimmune Disease”

Chairs:
Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany

Samik Basu, Cabaletta Bio, United States
“Resetting the Immune System: Insights into B-Cell Depletion After CD19-CAR T Therapy”

Christopher Sjöwall, Linköping University and Bristol-Myers Squibb, Sweden
“Current and Future Potential of CAR T-Cell Therapies in the Autoimmune Space”

Everett H Meyer, Stanford University, Stanford, CA, United States
“Regulatory T Cell Therapy in Action: Clinical Insights from GvHD to Autoimmunity”

Marco Becilli, Bambino Gesù Children’s Hospital, Rome, Italy
“Hit Hard, Hit Early: CAR T-Cell Therapy in Children with Autoimmune Disorders”

Jeffrey Dunn, Stanford University, Stanford, CA, United States
“Lessons from MS – Window of Opportunity for T Cell Interventions”

Aiden Haghikia, Hannover Medical School, Hannover, Germany
“Translating CAR T-Cell Therapy into Neuromuscular Diseases”

Chairs:
Sven Meuth, University of Münster, Münster, Germany
David Simon, Charité – Universitätsmedizin Berlin, Berlin, Germany

Georg Schett, University Hospital Erlangen, Erlangen, Germany
“Lupus in Remission – A New Immune Reality?”

Matteo Doglio, Ospedale San Raffaele, Milano, Italy
“Redirected Tregs as a Non-Cytotoxic Strategy to Reestablish Immune Homeostasis”

Axel Schambach, Hannover Medical School, Hannover, Germany
“Inject, Target, Reprogram: In Vivo CAR T Cells”

Maik Luu, University Hospital Würzburg, Würzburg, Germany
“Engineering Lessons from Oncology: Making CAR T-Cell Therapy Accessible and Effective in Autoimmunity”

Manel Juan, Hospital Clinic de Barcelona, Barcelona, Spain
“PoC Manufacturing: Can academia compete with pharma?”

Chair:
Tobias Alexander, Charité – Universitätsmedizin Berlin, Berlin, Germany
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany

Anna Rebecca Scheiwe, Fresenius Kabi, Germany
“Redefining Point of Care Manufacturing for CAR-T Immune Reset”

Gabriel Wong, AstraZeneca TITAN, Great Britain
“Target induced T-cell activating nanobody (TITAN): Next generation T-cell engager for autoimmune diseases”

Robert Zeiser, University of Freiburg Medical Center, Freiburg, Germany
“Preclinical Models for CRS & ICANS – Lessons Learned”

Remy Dulery, Dana-Farber Cancer Institute, Boston MA, USA
“Secondary Malignancies – Myth or Real Long-Term Concern?”

Melanie Hagen, University Hospital Erlangen, Erlangen, Germany
“New indications – new toxicities?”

Raffaella Greco, Ospedale San Raffaele, Milano, Italy
“EBMT Guidelines Revisited: When, who, and how.”

Chair:
Stephan Fricke, University Hospital Magdeburg, Magdeburg, Germany
Fabian Müller, University Hospital Erlangen, Erlangen, Germany

Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany

Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany

Dominique Farge, Assistance publique – Hôpitaux de Paris, Paris, France

Jeffrey Dunn, Stanford University, Stanford, CA, United States

Moderation:
Dimitrios Mougiakakos, University Hospital Magdeburg, Magdeburg, Germany